Search results

Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by diabetic macular oedema in adults.

Result type

Technology appraisal guidance

Published

22 July 2015

Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

Result type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.

Result type

Technology appraisal guidance

Published

14 September 2022

Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.

Result type

Technology appraisal guidance

Published

11 September 2024

Awaiting development [GID-TA11065] Expected publication date: TBC

Result type

Technology appraisal guidance

Status

Awaiting development

further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular...

Result type

Research recommendation

Published

9 June 2015

This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.

Result type

NICE guideline

Published

13 August 2024

further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema...

Result type

Research recommendation

Published

9 June 2015

degeneration (age-related) - ranibizumab and pegaptanib 30 June 2008 TA237 Macular oedema (diabetic) - ranibizumab: appeal...

Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.

Result type

Technology appraisal guidance

Published

27 July 2011

Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

Result type

Interventional procedures guidance

Published

19 May 2010

inconvenience, risk of adverse events and – especially when aflibercept or ranibizumab is used – substantial costs. People typically...

Result type

Research recommendation

Published

13 November 2018

This guidance has been updated and replaced by NICE technology appraisal guidance 274.

Result type

Technology appraisal guidance

Published

30 November 2011

NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

Result type

Medtech innovation briefing

Published

24 April 2018

further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with diabetic macular...